OP ED: Early Detection as a Public Health Imperative

Advancing Women's Health Through Awareness, Education, and Preventive Screening

By Catherine Crowley

Introduction

Women's health extends far beyond the diagnosis and treatment of disease. It encompasses a continuum of physical, psychological, environmental, and social factors that collectively influence health outcomes across the lifespan. Although advances in medical technology have dramatically improved the ability to identify disease at earlier stages, the effectiveness of these innovations ultimately depends upon one essential factor: awareness. Without public understanding of risk, screening opportunities, and preventive care, even the most sophisticated diagnostic tools remain underutilized.

As I began learning more about women's health through my involvement with the Women's Health Collaborative, I quickly recognized that one of the greatest barriers to improving health outcomes is not simply access to healthcare, but access to reliable knowledge. Health literacy empowers individuals to recognize risk, seek appropriate medical evaluation, and participate actively in decisions regarding their own care. Early detection therefore represents not merely a clinical objective, but a public health strategy that emphasizes education, prevention, and informed participation.

The future of women's healthcare will depend upon our collective ability to foster greater awareness before disease becomes clinically apparent.

---

Preventive medicine has fundamentally transformed modern healthcare by shifting attention from reactive treatment toward proactive surveillance. This transition reflects decades of epidemiological research demonstrating that many chronic diseases—including breast cancer, cardiovascular disease, osteoporosis, metabolic disorders, and numerous endocrine conditions—often develop silently before producing recognizable clinical symptoms. Consequently, the absence of symptoms should never be interpreted as evidence of the absence of disease.

Early detection programs have become central to this preventive model because they facilitate the identification of abnormalities during stages when intervention is generally more effective and treatment options are often less invasive. Screening therefore represents an opportunity to reduce disease burden before irreversible progression occurs. As reflected throughout my introduction to women's health education, routine examinations should not be viewed as responses to illness, but rather as investments in long-term wellness.

Breast cancer provides perhaps the most widely recognized example of the value of preventive screening. Mammography has served for decades as the cornerstone of population-based breast cancer screening, while complementary imaging modalities, including diagnostic ultrasound, continue to enhance clinical evaluation in appropriately selected patients. Importantly, screening examinations are performed in individuals without symptoms, distinguishing preventive surveillance from diagnostic investigations that are undertaken following the identification of a clinical concern. This distinction underscores the philosophical foundation of preventive medicine: identifying disease before patients recognize its presence.

Equally significant is the evolving understanding that disease risk extends well beyond hereditary predisposition. Although genetic susceptibility remains an important determinant of individual risk, contemporary research increasingly recognizes the influence of environmental exposures, occupational hazards, lifestyle factors, and cumulative toxicological burden on long-term health outcomes. These factors interact in complex ways that continue to be investigated across multiple scientific disciplines.

ENVIRONMENTAL IMPACT & RESPONSE
My own interest in environmental science has significantly shaped the way I think about women's health and disease prevention. As our understanding of environmental health continues to evolve, it has become increasingly clear that human health cannot be separated from the condition of the world in which we live. Pollution, persistent environmental contaminants, industrial chemicals, and other toxic exposures are often discussed in terms of their ecological consequences, yet their potential effects on human health deserve equal attention. The environment is not simply the backdrop of our lives—it is an active determinant of health that influences biological processes throughout the lifespan.

Scientific research has increasingly explored the relationship between environmental exposures and chronic disease, including cancers, endocrine disorders, reproductive health conditions, cardiovascular disease, and metabolic dysfunction. While genetics undoubtedly contribute to disease susceptibility, hereditary risk represents only one component of a far more complex interaction between biology, behavior, and environmental influences. Every day, individuals encounter countless environmental factors through the air they breathe, the water they consume, the foods they eat, and the products they use. Although the health effects of many individual exposures remain under investigation, the cumulative impact of lifelong environmental interactions has become an important area of public health research.

One of the greatest challenges in environmental medicine is that exposure histories are rarely straightforward. Many contaminants persist in soil, water, and air for years or even decades, making it difficult to determine precisely when, where, or to what extent an individual has been exposed. Furthermore, health consequences may not become apparent until many years after the initial exposure, complicating efforts to establish direct cause-and-effect relationships.

These uncertainties reinforce rather than diminish the importance of preventive healthcare. Because environmental risks cannot always be measured or completely avoided, early detection becomes an increasingly valuable strategy. Routine screening, preventive imaging, and ongoing health surveillance provide opportunities to identify disease before symptoms develop, allowing for earlier intervention and more favorable outcomes. From this perspective, environmental awareness and preventive medicine are complementary disciplines, united by a common objective: reducing disease burden through informed action, scientific understanding, and a proactive commitment to protecting long-term health.

PSA / Sponsor

HEALTH LITERACY
An equally important component of preventive healthcare is health literacy. The unprecedented accessibility of online information has created both opportunities and challenges for patients seeking to better understand their health. While digital resources have expanded access to medical knowledge, they have also increased exposure to misinformation, conflicting recommendations, and unsupported claims. Public health therefore depends not only upon the dissemination of information, but upon the dissemination of accurate, evidence-informed information delivered through credible educational initiatives.

Health advocacy fulfills a critical function within this framework. Effective advocates translate scientific knowledge into language that is understandable, actionable, and relevant to diverse communities. They encourage individuals to engage proactively with healthcare providers, participate in recommended screening programs, and appreciate the broader determinants of health that influence disease risk throughout life. Education consequently becomes a mechanism through which prevention is transformed from an abstract concept into practical action.

The societal consequences of delayed diagnosis extend well beyond individual patients. Cancer, in particular, illustrates the profound emotional, psychological, and social effects experienced by families and caregivers throughout the continuum of illness. Observing these experiences reinforces the importance of earlier intervention, not only to improve clinical outcomes but also to reduce the broader human burden associated with advanced disease. Preventive healthcare therefore benefits communities as much as individuals by preserving quality of life, maintaining productivity, and strengthening family support systems.

THE FUTURE OF WOMEN'S HEALTH: A COLLABORATIVE MODEL FOR PREVENTION
The future of women's health will increasingly depend upon interdisciplinary collaboration among clinicians, researchers, educators, public health advocates, and community organizations. Advances in diagnostic imaging, molecular medicine, environmental health research, and personalized risk assessment continue to expand opportunities for earlier disease recognition. However, technological innovation alone cannot improve outcomes unless individuals understand why preventive evaluation is necessary and are empowered to participate in it.

For this reason, awareness should be regarded as the first stage of prevention. Screening programs, educational initiatives, and community outreach collectively establish the foundation upon which successful preventive healthcare is built. Every informed decision to undergo appropriate screening represents an investment not only in individual health but also in the broader objective of reducing preventable morbidity and mortality.

Ultimately, early detection is not simply a diagnostic objective; it is a public health philosophy grounded in education, scientific evidence, and patient empowerment. By cultivating greater awareness, strengthening health literacy, and encouraging proactive participation in preventive care, we move closer to a healthcare system that identifies disease earlier, treats patients more effectively, and enables women to lead healthier lives throughout every stage of adulthood.

 

Spotlight: Cynthia Jean (PENDING APPROVAL- DO NOT DISTRIBUTE)

Turning Survival into a Mission of Hope

Some people survive cancer. Others spend the rest of their lives making sure fewer people have to face it alone. Cynthia Jean, LMSW, LSW. belongs firmly in the second category.

A licensed social worker, mental health advocate, breast cancer survivor, public speaker, and founder of Hope for Pink, Cynthia has transformed two deeply personal battles with breast cancer into a movement centered on education, advocacy, emotional support, and early detection. Her work extends far beyond awareness campaigns. She has become a trusted voice helping women—particularly younger women and those in underserved communities—navigate one of life's most frightening diagnoses with knowledge, confidence, and hope.

What distinguishes Cynthia is not simply that she survived cancer twice. It is that every chapter of her journey has strengthened her commitment to ensuring others receive the care, information, and emotional support she believes every patient deserves.

Listening Saved Her Life

Cynthia was only 33 years old when she noticed what seemed to be a small abnormality between her breasts. At first she assumed it was nothing serious—a pimple or minor skin irritation—but when it failed to disappear, she trusted her instincts and scheduled an appointment with her gynecologist.

That decision changed everything. Rather than dismissing her concerns because of her age, her physician chose to investigate further. Diagnostic imaging led to additional testing, ultimately revealing Stage II HER2-positive breast cancer.

For Cynthia, the experience reinforced one lesson she now shares with every woman she meets:

Listen to your body—and find healthcare providers who will listen to you. She credits those early conversations with physicians who respected her concerns as one of the reasons her cancer was identified when it still could be treated aggressively.

 

Facing Difficult Choices

Like many newly diagnosed patients, Cynthia suddenly found herself surrounded by opinions. Some encouraged the most aggressive surgical options immediately. Others presented more conservative alternatives. Rather than rushing into treatment, she sought physicians willing to educate her and present every available option.

She underwent chemotherapy, responded well to treatment, and successfully underwent breast-conserving surgery followed by additional therapy and radiation. Yet despite every effort, cancer returned several years later in the same region.

The recurrence forced another difficult series of decisions. This time Cynthia chose bilateral mastectomy with autologous tissue reconstruction, combined with additional immunotherapy and hormonal management. Today she remains in remission, maintaining a healthy lifestyle while continuing careful surveillance and encouraging others never to neglect routine follow-up care.

Rather than allowing recurrence to define her, she transformed it into renewed purpose.

 

Beyond Cancer Treatment

As a licensed social worker, Cynthia experienced survivorship from a perspective many clinicians never see. Cancer treatment eventually ends. Fear often does not. She speaks openly about scan anxiety, depression after treatment, changing identity, PTSD, and the emotional uncertainty that accompanies every follow-up examination. Many survivors struggle not because treatment failed, but because life afterward feels unfamiliar.

Patients are expected to celebrate survival while quietly carrying fears that few people fully understand.

For Cynthia, emotional recovery deserves the same attention as physical healing. Her work bridges mental health and oncology, recognizing that emotional wellness directly influences quality of life during and after cancer treatment. She regularly reminds survivors that healing extends beyond surgery, chemotherapy, or radiation—it includes rebuilding confidence, restoring identity, and learning how to move forward again.

 

Creating Hope for Pink

Following her own experience, Cynthia recognized another troubling reality. Most breast cancer organizations were primarily reaching older women, while younger patients—and particularly women from underserved communities—often felt invisible. She decided to change that.

Hope for Pink was created to bridge gaps in education, advocacy, and access. The organization focuses on helping younger women, minority populations, and underserved communities understand breast cancer risk, recognize warning signs, seek appropriate screening, and become active participants in their own healthcare decisions.

Equally important is Cynthia's emphasis on patient empowerment. She encourages every individual to ask questions, seek second opinions when necessary, and remember that no one has a greater stake in their health than they do themselves. "It's your life," she often reminds audiences. Healthcare decisions should be collaborative—not passive.

 

Advocacy through Action

Hope for Pink is far more than an educational nonprofit. Cynthia organizes community outreach events, wellness programs, fitness initiatives, educational workshops, and screening awareness campaigns throughout New York.

One of her signature programs, Sweats in Pink Awareness, combines physical activity with education by bringing together healthcare organizations, hospitals, wellness businesses, and community resources. Exercise serves not only as physical rehabilitation but also as a powerful strategy for improving mental health, reducing anxiety, and fostering resilience among survivors.

Her philosophy is refreshingly holistic. Movement improves mood. Community reduces isolation. Education replaces fear. Together, they become powerful medicine.

 

A Voice in Public Health

Cynthia's influence extends well beyond community events. She serves on the New York City Breast Cancer Task Force, collaborating with hospitals, physicians, researchers, nonprofits, and civic leaders to reduce breast cancer mortality throughout New York City. The task force focuses on improving access to screening, accelerating diagnosis, and strengthening pathways into treatment. She is also an active member of the American Cancer Society National Breast Cancer Roundtable, contributing to nationwide conversations about prevention, survivorship, patient support, and equitable healthcare access.

These leadership roles allow Cynthia to advocate for meaningful policy improvements while ensuring the voices of survivors remain central to discussions about cancer care.

 

Meeting Women Where They Are

Perhaps Cynthia's greatest strength lies in her ability to meet people before they become patients. She attends community events, health fairs, and neighborhood gatherings, encouraging women to schedule screenings before symptoms appear. Rather than relying on fear, she speaks honestly about peace of mind.

A few minutes spent obtaining a mammogram—or any appropriate screening—may prevent months or years of uncertainty later. She understands why many women postpone testing because she has heard every concern: fear of pain, fear of diagnosis, fear of the unknown. Her answer is always compassionate but consistent. The unknown is almost always more frightening than the truth.

 

Looking Forward

During discussions with fellow advocates and clinicians, Cynthia continues exploring innovative ways to expand access to early detection, including portable imaging technologies capable of bringing screening directly into underserved neighborhoods and community events. She believes healthcare should move closer to patients—not expect patients to overcome every barrier alone. That philosophy captures the essence of her life's work.

She is not simply building another nonprofit. She is building trust. She is teaching people to advocate for themselves. She is helping survivors rediscover hope after diagnosis. Most importantly, Cynthia Jean reminds us that breast cancer advocacy is not measured solely by fundraising or awareness campaigns. Its true impact is found in every conversation that encourages someone to schedule a screening, seek a second opinion, ask another question, or refuse to ignore what their body is trying to say.

Her story is one of survival. Her legacy is becoming one of empowerment.

Cynthia Jean, LMSW, LSW  |  Spring Forward Hope for Pink  |  hopeforpink.org

 

Women's Mental Health: The Missing Link Across Every Specialty of Healthcare

 Why Emotional Wellness Must Be Integrated into Prevention, Rehabilitation, and Restorative Medicine

By Jessica Connell, LCSW

Women's healthcare has evolved tremendously over the past several decades, yet one critical component continues to remain underrepresented across nearly every specialty: mental health. Whether a woman is navigating cancer treatment, cardiac rehabilitation, chronic pain, menopause, infertility, autoimmune disease, weight management, neurological disorders, or physical rehabilitation, her emotional well-being profoundly influences both her quality of life and her clinical outcomes.

As a licensed clinical social worker, I have seen firsthand that mental health is not simply another specialty—it is the thread that connects every aspect of healing.

Women often arrive in medical settings carrying invisible burdens that extend far beyond the diagnosis documented in their medical chart. They may be balancing careers, caregiving responsibilities, financial pressures, parenting demands, relationship challenges, trauma histories, hormonal changes, or chronic stress while attempting to recover from illness. These emotional realities directly affect motivation, resilience, treatment adherence, pain perception, sleep quality, and even immune function.

Unfortunately, these struggles frequently go unnoticed. Historically, women have been among the most underdiagnosed and underserved populations in healthcare. For generations, women's symptoms have too often been minimized, misunderstood, or attributed solely to stress or anxiety without a comprehensive evaluation. Heart disease in women, autoimmune disorders, endometriosis, chronic pelvic pain, menopause-related cognitive changes, and numerous pain conditions have all experienced significant delays in recognition compared to their male counterparts.

The emotional consequences of these experiences can be profound.

When individuals feel dismissed or misunderstood, they begin questioning their own experiences. Self-doubt, anxiety, depression, frustration, and hopelessness frequently follow, creating barriers to recovery that no medication alone can resolve.

This is why mental health professionals should not be viewed as an optional referral after medical treatment has failed. We should be integrated members of multidisciplinary healthcare teams from the very beginning.

Every specialty benefits when psychological care becomes part of comprehensive treatment. In oncology, counseling helps patients process fear, uncertainty, body image changes, survivorship, and family dynamics. In rehabilitation medicine, emotional resilience often determines whether individuals remain engaged in demanding recovery programs. In obesity medicine, sustainable change requires addressing emotional eating, self-worth, trauma, and lifelong behavioral patterns rather than focusing exclusively on calories and exercise. Women navigating menopause frequently experience mood fluctuations, sleep disturbances, cognitive concerns, and shifting identities that deserve both medical and psychological support.

Similarly, women managing autoimmune diseases, chronic pain syndromes, neurological disorders, pelvic floor dysfunction, infertility, or cardiovascular disease often benefit from interventions that strengthen coping skills, reduce stress, improve communication, and restore confidence throughout treatment.

Mental health does not replace medical care—it amplifies its effectiveness. Today's healthcare environment increasingly recognizes that healing occurs through collaboration. Physicians, rehabilitation specialists, nutritionists, nurses, physical therapists, psychologists, social workers, health coaches, and wellness professionals each contribute unique expertise that together produces outcomes no single discipline can achieve alone.

Women's health deserves this level of integration. Equally important is recognizing that emotional wellness extends beyond managing anxiety or depression. It encompasses self-esteem, relationships, sexuality, identity, grief, resilience, caregiver fatigue, workplace stress, trauma recovery, confidence, and the ability to adapt during life's transitions. Supporting these dimensions allows women not merely to survive illness but to rebuild fulfilling, meaningful lives.

The future of women's healthcare must move beyond treating isolated diagnoses toward caring for the whole woman. This vision is precisely why collaborative women's health programs are becoming increasingly important. By bringing together experts across diagnostic imaging, rehabilitation, nutrition, cardiology, oncology, endocrinology, sexual health, mental health, and restorative medicine, we create an environment where women are finally seen in their entirety—not simply as patients with a condition, but as individuals with complex biological, psychological, and social needs.

When mental health becomes embedded within every specialized program, we reduce barriers to care, improve patient engagement, strengthen long-term outcomes, and help women reclaim confidence in their health journeys.

The most effective healthcare doesn't simply treat disease. It restores hope, resilience, and quality of life. For women—particularly those whose concerns have too often been overlooked—that comprehensive, compassionate approach is not merely beneficial. It is essential.

Video gallery for internal use only: Dr. Bobbi Kline

Occupational Exposures- intro for "Get Checked Now!"

Only the facts about MENOPAUSE

Only the facts about CANCER (and STRESS)

A Speculative Minireview on Potential Anti-Breast Cancer Botanicals in New York State

The Women's Health Collaborative is a proud supporter of clinical and academic research to help advance new solutions for breast cancer treatments. Publishing information about current findings and exploratory processes aid in the expansion of public knowledge and potential resources to encourage the active studies in the continuing search for a cure. The editors of the Women's Health Digest shares this feature and endorses the efforts of the authors for their advocacy and their commitment to pursue this expanding study.

RESEARCH REVIEW:

THERAPEUTIC POTENTIALS OF ECHINACEA, BLACK COHOSH, AND BURDOCK

Authors: Noelle Cutter, Phd, Alexandra Fiederlein

Abstract
This minireview explores the therapeutic potential of three botanicals—Echinacea, Black Cohosh, and Burdock—found in or cultivated in New York State (NYS) for their potential anti-breast cancer properties. Each botanical demonstrates distinct mechanisms of action, including anti-inflammatory, antioxidant, cytotoxic, and apoptotic effects, as well as modulation of signaling pathways such as PI3K/Akt and STAT3. While preclinical studies reveal promising results, inconsistencies due to varying extraction methods, study designs, and plant parts highlight the need for standardized research protocols and clinical trials. Additionally, the potential dual effects of phytoestrogens and interactions with existing treatments underline the importance of evidence-based application. This review provides a foundational understanding of these botanicals and their implications for advancing breast cancer therapy.

Introduction
Breast cancer remains one of the leading causes of cancer-related deaths worldwide. Despite advancements in treatment, resistance to conventional therapies such as chemotherapy and targeted drugs presents a significant challenge (Siegel et al., 2021). Thus, there is an urgent need for alternative therapeutic strategies that are effective, have fewer side effects, and overcome resistance mechanisms. Natural products derived from plants have been recognized as a rich source of novel anticancer agents, with several drugs like Paclitaxel (Taxol®) being derived from plant sources (Cragg & Newman, 2013).

The history of plant-derived medicines highlights the immense potential of botanicals in cancer treatment. For instance, Vincristine and Vinblastine, derived from the Madagascar periwinkle (Catharanthus roseus), have become cornerstone treatments for certain cancers (Cragg & Newman, 2013). Similarly, the success of Taxol underscores the value of exploring natural compounds for therapeutic breakthroughs. Despite these advances, many plant species remain underexplored, particularly in regions like Long Island, New York, which boasts unique environmental conditions that may yield novel bioactive compounds.

Current breast cancer therapies, including chemotherapy, hormone therapy, and targeted treatments, are often accompanied by severe side effects and limited efficacy in drug-resistant cases (Hassan et al., 2020). Phytochemicals, such as flavonoids, alkaloids, and terpenoids, have demonstrated promising anticancer activities, including the induction of apoptosis, cell cycle arrest, and the modulation of critical signaling pathways like PI3K/Akt and NF-κB (Hassan et al., 2020). These compounds offer a potentially safer and more targeted approach to cancer treatment.

The flora of Long Island represents an untapped reservoir of medicinal plants with potential anticancer properties. Regional biodiversity, influenced by distinct climatic and soil conditions, may enhance the therapeutic potential of local botanicals. Exploring this diversity could lead to the discovery of novel plant-based therapies that complement existing treatment regimens. This review aims to explore the medicinal potential of selected botanicals, including Echinacea, Black Cohosh, and Burdock, with a focus on their mechanisms of action and implications for breast cancer treatment.

________________________________________

Research Problem
The challenge of breast cancer treatment is compounded by the emergence of multidrug resistance and the severe side effects associated with existing therapies. Natural plant extracts have shown promise in combating cancer cells through various mechanisms, including apoptosis induction, cell cycle arrest, and modulation of signaling pathways (Hassan et al., 2020). The flora of Long Island remains largely untapped in the search for anticancer compounds, providing an opportunity to explore and identify novel plant extracts with therapeutic potential against breast cancer.

________________________________________

Potential Anti-Breast Cancer Botanicals Located in NYS

Echinacea
Echinacea, though not native to NYS, is grown in upstate New York and Long Island (Werier et al., n.d.). The two species, Echinacea pallida and Echinacea purpurea, possess flavonoids, caffeic acid derivatives, and polysaccharides that contribute to immune activation, antioxidant effects, and anti-inflammatory properties (Islam et al., 2020; Karimi et al., 2019).

Recent studies demonstrate E. purpurea's selective toxicity against breast cancer cells while protecting noncancerous cells (Park et al., 2020). Additionally, extracts from E. pallida and E. purpurea show promising cytotoxic and apoptotic effects on MCF-7 and BT-549 breast cancer cell lines (Driggins et al., 2021). Further research on secondary metabolites, such as polyacetylenes, indicates concentration-dependent cytotoxicity (Pellati et al., 2018).

Despite these promising findings, some studies report conflicting outcomes. For instance, certain phenolic components of Echinacea angustifolia might counteract chemotherapy drugs like doxorubicin, suggesting a need for caution and more standardized research protocols (Espinosa-Paredes et al., 2021).

Black Cohosh
Black Cohosh (Actaea racemosa), found in various NYS regions, has triterpene glycosides and polyphenolic compounds that exhibit potential anti-breast cancer effects (Kuhn et al., 2021). Mechanistic studies suggest Black Cohosh may act as a selective estrogen receptor modulator (SERM) or exert anti-estrogenic effects, depending on the context (Zierau et al., 2019).

For instance, Crone et al. (2020) demonstrated that Black Cohosh decreases ER-α and PR expression in MCF-7 cells while inhibiting cell proliferation. Studies on triterpene glycosides such as actein reveal significant anti-proliferative and anti-metastatic activity in HER2-overexpressing cell lines (Einbond et al., 2018). However, certain studies note potential risks, such as increased metastatic activity in specific breast cancer subtypes like HER2+ (Davis et al., 2021).

The clinical safety and efficacy of Black Cohosh remain areas of ongoing investigation. While some trials report reduced menopausal symptoms in breast cancer patients taking tamoxifen, others find no significant benefit in managing symptoms like hot flashes (Rostock et al., 2019).

Burdock
Burdock (Arctium lappa), common in upstate NY, is recognized for its phenolic compounds, lignans, and terpenoids that contribute to its antioxidant, anticancer, and anti-inflammatory activities (Predes et al., 2019; Knipping et al., 2020).

Arctigenin, a major active constituent, shows anti-metastatic and apoptotic activity in MCF-7 and MDA-MB-231 cell lines. Mechanistically, arctigenin inhibits MMP-2 and MMP-9 activity, reduces VEGF expression, and targets pathways such as PI3K/Akt and STAT3 (Lou et al., 2020; Maxwell et al., 2020). Synergistic effects of arctigenin with chemotherapy drugs like doxorubicin further enhance its therapeutic potential (Lee et al., 2021).

While arctigenin exhibits significant promise, its classification as a phytoestrogen raises concerns about its safety in hormone-sensitive breast cancers. Further clinical trials are necessary to evaluate its efficacy and address these safety concerns (Maxwell et al., 2020).

________________________________________

Conclusion
The review highlights the therapeutic potential of botanicals such as Echinacea, Black Cohosh, and Burdock in breast cancer treatment. While preclinical studies offer promising results, inconsistencies in data due to varying extraction methods, study protocols, and plant parts underscore the need for standardized research and clinical trials. The dual effects of phytoestrogens and potential interactions with existing treatments emphasize the importance of cautious, evidence-based applications of these botanicals.

________________________________________

Future Research

Future research should aim to address the following gaps and challenges:

1. Standardization of Extraction Methods: Establishing uniform protocols for plant part selection, extraction techniques, and phytochemical profiling to ensure consistency across studies.

2. Clinical Trials: Conducting randomized controlled trials to evaluate the efficacy and safety of these botanicals in diverse patient populations, including hormone-sensitive and resistant breast cancer subtypes.

3. Mechanistic Studies: Further exploring molecular pathways modulated by these botanicals to understand their anti-cancer mechanisms and interactions with conventional therapies.

4. Phytoestrogen Safety: Investigating the dual role of phytoestrogens to delineate their potential risks and benefits, particularly in hormone-sensitive breast cancers.

5. Synergistic Effects: Assessing the potential synergistic effects of these botanicals with chemotherapy or immunotherapy agents to optimize treatment outcomes.

6. Long-term Effects: Evaluating the long-term safety and efficacy of these botanicals in breast cancer prevention and recurrence.

7. Geographic Variation: Investigating how regional differences in soil and climate affect the phytochemical composition and therapeutic efficacy of these plants.

________________________________________

References

Cragg, G. M., & Newman, D. J. (2013). Natural products: A continuing source of novel drug leads. Biochimica et Biophysica Acta (BBA)-General Subjects, 1830(6), 3670-3695.

Davis, E. L., et al. (2021). Evaluating metastatic risks of Black Cohosh in HER2+ breast cancer. Cancer Biology & Therapy, 20(4), 300-310.

Driggins, J., et al. (2021). The anti-proliferative effect of Echinacea pallida on BT-549 cancer cell lines. Herbal Medicine Research, 8(2), 145-160.

Espinosa-Paredes, E., et al. (2021). Synergistic effects of Echinacea angustifolia extracts with chemotherapy drugs. Cancer Treatment Reviews, 52, 45-60.

Hassan, S. S., et al. (2020). Plant-derived compounds as potential anticancer agents. Frontiers in Pharmacology, 11, 573196.

Islam, S., et al. (2020). Phytochemical properties of Echinacea species. Pharmacognosy Reviews, 14(4), 210-220.

Karimi, S., et al. (2019). Enhancing flavonoid content in Echinacea purpurea using ZnO nanoparticles. Plant Biotechnology Reports, 13(2), 180-195.

Knipping, K., et al. (2020). Anti-inflammatory and anticancer properties of burdock root. Journal of Medicinal Plants Research, 14(5), 300-312.

Lou, Z., et al. (2020). Anti-metastatic effects of arctigenin on human breast cancer cell lines. Molecular Carcinogenesis, 59(8), 905-915.

Maxwell, S., et al. (2020). Arctigenin inhibits the activation of the mTOR pathway. Breast Cancer Research, 22(5), 102-115.

Park, K., et al. (2020). Selective cytotoxic effects of Echinacea purpurea on breast cancer cells. Phytotherapy Research, 34(10), 2723-2730.

Pellati, F., et al. (2018). Secondary metabolites from Echinacea species: Cytotoxic effects on breast cancer cell lines. Journal of Ethnopharmacology, 213, 165-175.

Predes, F. S., et al. (2019). Burdock’s cytotoxic effects on breast cancer cell lines. Phytomedicine, 62, 152-160.

Rostock, M., et al. (2019). Black Cohosh use in breast cancer patients: A systematic review. Supportive Care in Cancer, 27(9), 3585-3597.

Siegel, R. L., Miller, K. D., & Jemal, A. (2021). Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7-33.

Werier, D., et al. (n.d.). The flora of New York: A survey of native and non-native species. New York Flora Atlas. Retrieved from https://newyorkfloraatlas.org

Zierau, O., et al. (2019). Black Cohosh: Anti-estrogenic or estrogenic effects? Phytotherapy Research, 33(7), 200-212.

"BOTH MY PARENTS HAD CANCER... I NEED TO TEST!

INTRODUCTION'

According to the NIH, "About 8% to 10% of all cancers in children overall are caused by an inherited pathogenic variant (harmful alteration) in a cancer predisposition gene, although the percentage varies across cancer types (7–9)" [1]. As cancer rates remain prevalent in certain geographic areas and demographic groups, gene testing and functional genomics are some of today's most helpful tools that help support early detection and prevention.  To find comprehensive answers about one's health, subscribing to a personalized gene testing program is advantageous especially with familial links to cancer.  The concept of "TEST, DON'T GUESS" is the rallying message from the cancer care community, and with today's highly advanced diagnostic and testing solutions available, staying proactive is the key to health success.

We thank the Women's Health Collaborative (cancer care group), BardDiagnostics and the Integrative Cancer Resource Society for their outreach work in spreading the message about personalized gene testing in the next generation of parents have had a bout with cancer.

SAMANTHA'S TEST

Originally published in Health Resource Digest (5/1/2024)

Samantha Hunt, 24 is a young cancer awareness advocate due mostly to the upbringing of two cancer survivors who are outspoken about environmental cancers and proactive testing ("Get Checked NOW!" program).  She is in a graduate program for social work and grew up in a household in support of prevention and early detection.

Since she was 9 years old, Samantha took on personal studies on breast cancer when she watched her mother (Jennifer) undergo a bilateral mastectomy for early-stage breast cancer.  Samantha's father was diagnosed with early-stage prostate cancer, and her maternal aunt also had breast cancer. By her late teens into her college years, Samantha was convinced that she needed to have early screening, which is when she discovered she had dense breast tissue- a condition that is present in over half of women in the U.S.  [12]

Though currently testing negative for cancer, Samantha continues to undergo early detection through gene testing, ultrasound screening and maintains a significantly strict lifestyle of prevention (eating healthy/organic foods, no sugar, exercise, organic foods etc).  Early in life, she learned the value of staying proactive and getting a second opinion- never resting on reassuring words from physicians.  "Early on, my gyno didn't express any real sense of urgency about me getting an ultrasound test but gave me the referral just to make me happy...", stated Ms. Hunt.  "Even today (and sometimes even in the past with other breast exams), I often feel like they do it so quickly and carelessly, and I feel stressed out after...  I'm not convinced that I'm getting a proper examination!"

Samantha has received a total of 4 biopsies due to the "abnormally dense" breast tissue- a concern that scientists are now linking to breast cancer. [13] At an early age, Samantha took on a significant leadership role in her health to approve the biopsies despite the risk and concerns from her parents. "After my first sono, they found me to be 'very lumpy' and called on me to get a biopsy.  None of us were excited about this but if I was going to get any peace of mind, I made a decision to go for it and I'm glad I did. Honestly think I'd be more anxious knowing there's something that a doctor recommended that I should get a biopsy on!"

EPILOGUE
To pursue gene testing in the younger ages (of parents who struggle with or have survived cancer) is a matter of choice and one that is not necessarily to be taken as an emergency alert. Samantha's story is her own- and her journey to explore her own genetic makeup comes from a proactive young woman whose decision is partly based on other findings like dense breast tissue.  Samantha's parents (both cancer survivors and public advocates) highly support their daughter to "get the test" as a road to getting peace of mind.  Their pursuit for a proactive lifestyle encourages a smarter, healthy diet and a preventive life strategy that continues into their next generation.   

To date, Samantha's gene test reports have concluded no alarming traces of cancer predisposition.  She continues to maintain a proactive life, staying on top of physical checkups and an all-natural lifestyle.

---

Thursday, March 14, 2024

CANCER PREDISPOSITION, HEREDITY & GENE TESTING

NYCRA NEWS- Genetic Predisposition (Vol. 1- Spring Issue 2024)

By definition, diseases like CANCER are not directly hereditary. Unlike genetic traits and characteristics passed down to children like blood type and eye color, chronic diseases like cancer are recognized to be contracted through the environment (external impact). However, as cancer is a form of genetic mutation, genetic changes that increase the risk of cancer CAN be passed down or inherited.  

When a specific cancer type is prevalent in one side of the family, the cancer is recognized as a FAMILIAL cancer. Most of them are caused by genetic mutation in a gene related to cancer susceptibility. In addition, a term called "family cancer syndrome" (or "hereditary cancer syndrome") is a rare disorder in which family members have an above-average chance of developing a certain type or types of cancer. Family cancer syndromes are caused by inherited genetic variants in certain cancer-related genes. [1]

It is reported that up to 10% of all cancer cases may be caused by inherited genetic mutation or changes. These are called CANCER PREDISPOSITION genes. Individuals who carry a mutant allele of these genes have an increased susceptibility to cancer. It is now widely identified that an accumulation of genetic or epigenetic alterations affect the conversion of normal cells to cancer cells. [2]

 GETETIC MUTATIONS

Oftentimes, researchers of hereditary cancers will reference breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2).  Specific alterations in these genes disable their function such that, inheriting such mutations may preclude you to contract breast (and other) cancers. Having a strong history of breast cancer may often be linked to acquiring a BRCA1 or BRCA2 mutation. Family members with BRCA1 or BRCA2 mutations often share the same mutation. [3]

Another predisposition scenario is Lynch syndrome; according to the CDC, carrying this condition holds a 1 in 2 (50%) heredity chance of your children also having Lynch syndrome. Genetic testing for Lynch syndrome can be considered once your children reach adulthood.  Similarly, the most common are hereditary breast and ovarian cancer (HBOC) syndrome. Anyone with HBOC syndrome holds a higher risk for breast and ovarian as well as advanced and pancreatic cancers. [4]

GENE TESTING FOR CANCER RISK

Today's advancements in genetic tests can determine the possibility of an elevated risk of cancer. For those who come from a family with a history of breast and ovarian cancer make screening and treatment decisions. Not everyone needs to get genetic testing for cancer risk. Your doctor or health care provider can help you decide if you should get tested for genetic changes that increase cancer risk. They will likely ask if you have certain patterns in your personal or family medical history, such as cancer at an unusually young age or several relatives with the same kind of cancer.

Physicians may recommend genetic testing. It is advised to start with a genetic counselor who presents the potential risks, benefits, and drawbacks of genetic testing in your situation. Genetic counselors are also trained to review genetic test results with patients and/or their families and provide guidance in decision-making from those results. There are at-home genetic tests that one can order directly. Thanks to Dr. Google, there's more information on the types of consumer-accessible tests on the market- but these tests may have drawbacks or limitations when it comes to the prospect of genetic predisposition and genetic changes that increases cancer risk. Genetic counselors may be a helpful resource for identifying these test products as well.

For more information on what tests are available and who may want to consider them, visit the NIH/NCA Genetic Testing for Inherited Cancer Susceptibility Syndromes. https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet

REFERENCES

1) The Genetics of Cancer: NIH- https://www.cancer.gov/about-cancer/causes-prevention/genetics#:~:text=A%20family%20cancer%20syndrome%2C%20also,in%20certain%20cancer%2Drelated%20genes.  The Genetics of Cancer |  2) Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes - Published online 2015 Nov 30. doi: 10.1038/aps.2015.89 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753377/#:~:text=Up%20to%2010%25%20of%20cancers,an%20increased%20susceptibility%20to%20cancer. |  3) Family Health History and the BRCA1 and BRCA2 genes/ CDC Centers for Disease Control and Prevention- https://www.cdc.gov/genomics/disease/breast_ovarian_cancer/fam_hist_genes.htm#:~:text=Normally%2C%20the%20BRCA1%20and%20BRCA2,%2C%20ovarian%2C%20and%20other%20cancers. |  4) Family Health History and Cancer: Which Hereditary Conditions Raise My Chances of Getting Cancer? / CDC Centers for Disease Control and Prevention-  https://www.cdc.gov/cancer/family-health-history/index.htm#:~:text=Several%20hereditary%20conditions%20can%20raise,advanced%20prostate%2C%20and%20pancreatic%20cancers.

Part 2: CANCER PREDISPOSITION & THE ROLE OF GENETIC TESTING

By: Roberta Kline, MD 

Cancer comes from one of two ways. One is that you have inherited genetic mutations that significantly increase your risk for specific types of cancer. But overall, that's a minority of cancer cases. The majority of cancers occur because of an interaction between your individual genes and the environment that they've been exposed to throughout your lifetime. Both of them can be tested for.  And if you know what you're dealing with, you can create a plan that's specific for you that enables you to be proactive. This enables you to have that locus of control that you know what's going on in your body, but you don't know if you don't test. Therefore, TEST- DON'T GUESS!  And then you can create your roadmap that works for you.

Especially with breast cancer, we know that 90% of the cases are not due to known inherited genetic mutations like BRCA1. The majority of them are due to very small changes in your DNA that interact with your environment over your lifetime that predispose you to developing breast cancer. But if you don't know that you have these predispositions, you can unknowingly be exacerbating the problem. If you've been tested and you know what your genes are doing, you can proactively create a plan to minimize your risk throughout your lifetime. 

"INHERITING CANCER & GETTING THE RIGHT TEST"

We understand genetic mutations to cause severe diseases, predominantly causing certain types of cancers. But rather than living in fear of what you may or may not have inherited from your parents, and whether you may or may not develop the same diseases that they carried- get tested, so you won't find yourself guessing.  Through gene testing protocols, you can precisely identify where you need to focus your resources, your attention- and when you can let go of that (unnecessary) fear.

Because genetic testing can be very specific, one of the biggest challenges for proactive people about their health is to know WHAT to test for. What test do you use? Is there a test that's better for you than others? These are important questions and the amount of information available (while great) can be quite overwhelming. The best suggestion is to speak to a trained medical professional or a genetic specialist who can help you navigate through the vast collection of available tests to find what is right for you.  What you want is a test that has value. And in order to have value, it needs to answer your questions and provide you a roadmap for what you can do proactively for your health for the future. 

DNA REACTIONS FROM ENVIRONMENTAL TOXINS:

So when you look at the issue of breast cancer in Long Island and how it is tied to these environmental toxins, what you're seeing is these environmental toxins can potentially, if it's a large enough dose, create mutations in somebody's DNA, but what is most likely happening (and this I do have to check on,) what is most likely happening is it's overwhelming the body's ability to process these toxins. When your body processes any kind of chemical, including these toxins, it produces oxidative stress. When you have too much oxidative stress for your body to handle, this has a tendency of creating DNA breaks. So it's not the toxin directly causing DNA breaks necessarily, it's that your body can't get rid of that toxin fast enough or efficiently enough. And so its own biological processes that are supposed to deal with this are the ones that actually cause the DNA breaks (mutation) and the changes in the DNA that increase the risk of breast cancer. 

 This is the second part of that pathway by which estrogen as well as other chemicals can cause breast cancer.  Conventional medicine pays attention to the binding of estrogen to the estrogen receptor causing proliferation. Excessive proliferation can lead to a higher chance of DNA breaks. Every time that DNA replicates, (which is what happens when you create proliferation) when the cells grow, every time that DNA replicates, there's a chance that it will cause an error in that replication and leave a mutation in the DNA. Now, we have lots of processes that are built in to safeguard against that. We have DNA repair mechanisms, we have all sorts of machinery that is designed to catch breaks in the DNA before they get integrated into the person's biology. If you overwhelm that, those breaks stay. 

To note, estrogen itself is a toxin, even though we produce it ourselves. Studying the other part of estrogen metabolism, which is the same process that happens with all of these toxins is that it goes through what we call DETOXIFICATION or BIOTRANSFORMATION. You're transforming something that's potentially toxic, ultimately into a molecule or a chemical that is non-toxic and gets eliminated from the body. Within that process, you are often creating even more toxic chemicals in the intermediary stages, and that's what requires a high level of antioxidant defense as well as other biological systems to keep those contained and keep them in check and funnel them quickly into the benign molecules out of the body. This is the second way that you can create DNA damage that you can create cancer because you are overwhelming the body's ability to neutralize those toxic compounds that your body is creating as a result of whatever it's taking in. This has to do with oxidative stress, which is linked to INFLAMMATION, which we know underlies almost every cancer process. 

ABOUT THE AUTHOR

ROBERTA KLINE, MD (Educational Dir. /Women's Diagnostic Group) is a board-certified ObGyn physician, Integrative Personalized Medicine expert, consultant, author, and educator whose mission is to change how we approach health and deliver healthcare. She helped to create the Integrative & Functional Medicine program for a family practice residency, has consulted with Sodexo to implement the first personalized nutrition menu for healthcare facilities, and serves as Education Director for several organizations including the Women’s Diagnostic Health Network, Mommies on a Mission. Learn more at https://robertaklinemd.com/